Genomes and Genes
Summary: Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Publications359 found, 100 shown here
- Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosisPatricia J Campbell
Mycobacteriology Laboratory Branch, Division of Tuberculosis Elimination, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Bldg 17, Room 4029, M S F08, Atlanta, GA 30333, USA
Antimicrob Agents Chemother 55:2032-41. 2011..We used DNA sequencing to detect resistance to the first-line antituberculosis drugs isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB) and the second-line drugs amikacin (AMK), ..
- Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosisDaphne Yee
Respiratory Epidemiology Unit, Montreal Chest Institute, 1110 Pine Avenue West, Room 103, Montreal, PQ, H3A 1A3 Canada
Am J Respir Crit Care Med 167:1472-7. 2003..31 to 1.61) for pyrazinamide, compared with 0.49 (95% CI, 0.42 to 0.55) for isoniazid, 0.43 (95% CI, 0.37 to 0.49) for rifampin, and 0.07 (95% CI, 0.04 to 0.10) for ethambutol...
- Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countriesM A Espinal
World Health Organization, Communicable Diseases Programme, Ave Appia 20, 1211 Geneva 27, Switzerland
JAMA 283:2537-45. 2000....
- Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South AfricaMarinus Barnard
Foundation for Innovative New Diagnostics, 71 av Louis Casai, 1216 Cointrin, Switzerland
Am J Respir Crit Care Med 177:787-92. 2008..Conventional methods for detecting Mycobacterium tuberculosis drug resistance take weeks to months to produce results. Rapid molecular testing for drug resistance is available but has not been implemented in high-TB-burden settings...
- Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosisSusan E Dorman
Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland 21231, USA
Am J Respir Crit Care Med 180:273-80. 2009..Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis (TB) chemotherapy, but data regarding its activity in humans are limited...
- Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohortJonathan E Golub
Johns Hopkins University, School of Medicine, 1550 Orleans St, 1M 07 Baltimore, MD 21231, USA
AIDS 23:631-6. 2009The World Health Organization recommends isoniazid preventive therapy (IPT) for preventing tuberculosis in HIV-infected adults, although few countries have instituted this policy...
- GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysisD I Ling
Dept of Epidemiology, Biostatistics and Occupational Health, McGill University, 1020 Pine Avenue West, Montreal, QC H3A 1A2, Canada
Eur Respir J 32:1165-74. 2008..After the literature searches, 14 comparisons for rifampicin and 15 comparisons for isoniazid were identified in 10 articles that used GenoType MTBDR assays...
- Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk Richard J Sylvester
EORTC Headquarters, Brussels, Belgium
Eur Urol 57:766-73. 2010....
- Relationship between mutation of serine residue at 315th position in M. tuberculosis catalase-peroxidase enzyme and Isoniazid susceptibility: an in silico analysisRituraj Purohit
School of Bio Sciences and Technology, Bioinformatics Division, Vellore Institute of Technology University, Vellore, 632014 Tamil Nadu, India
J Mol Model 17:869-77. 2011..It is known that, activation of Isoniazid (INH) is mediated by Mycobacterium tuberculosis catalase-peroxidase (MtBKatG) and mutation at position 315 (..
- Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resourcesStephen D Lawn
Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Cape Town, South Africa
Lancet Infect Dis 10:489-98. 2010Antiretroviral therapy and isoniazid preventive therapy (IPT) are both effective interventions to prevent HIV-associated tuberculosis, but work via different mechanisms...
- Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatmentA Trajman
Pró reitoria de Saúde, Gama Filho University, Brazil
Int J Tuberc Lung Dis 14:551-9. 2010..Randomised controlled trial of latent tuberculosis infection (LTBI) treatment in 10 clinics in Canada, Saudi Arabia and Brazil...
- Contact screening and chemoprophylaxis in India's Revised Tuberculosis Control Programme: a situational analysisV V Banu Rekha
Tuberculosis Research Centre, Chennai, India
Int J Tuberc Lung Dis 13:1507-12. 2009..RNTCP) recommends screening of all household contacts of smear-positive pulmonary tuberculosis (PTB) cases for tuberculosis (TB) disease, and 6-month isoniazid preventive therapy (IPT) for asymptomatic children aged <6 years.
- Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in BrazilRosilene Fressatti Cardoso
Department of Clincal Analysis, State University of Maringa, Parana, Brazil
Antimicrob Agents Chemother 48:3373-81. 2004..in the genes katG, inhA (regulatory and structural regions), and kasA and the oxyR-ahpC intergenic region of 97 isoniazid (INH)-resistant and 60 INH-susceptible Mycobacterium tuberculosis isolates obtained in two states in Brazil: Sã..
- Adherence to anti-tuberculosis chemoprophylaxis and treatment in childrenS Van Zyl
Desmond Tutu TB Centre, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa
Int J Tuberc Lung Dis 10:13-8. 2006..Limited data exist on adherence to anti-tuberculosis treatment and chemoprophylaxis in children in high-burden settings...
- Antituberculosis drugs and hepatotoxicityWing Wai Yew
Tuberculosis and Chest Unit, Grantham Hospital, Hong Kong, China
Respirology 11:699-707. 2006b>Isoniazid, pyrazinamide and rifampicin have hepatotoxic potential, and can lead to such reactions during antituberculosis chemotherapy...
- 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trialTaraz Samandari
Botswana USA Partnership BOTUSA, Gaborone and Francistown, Botswana
Lancet 377:1588-98. 2011In accordance with WHO guidelines, people with HIV infection in Botswana receive daily isoniazid preventive therapy against tuberculosis without obtaining a tuberculin skin test, but duration of prophylaxis is restricted to 6 months...
- Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic diseaseElizabeth L Corbett
London School of Hygiene and Tropical Medicine, London, United Kingdom
PLoS Med 4:e22. 2007..We investigated the epidemiology of prevalent and incident TB in a high HIV prevalence population provided with enhanced primary health care...
- Adherence to isoniazid preventive chemotherapy: a prospective community based studyB J Marais
Desmond Tutu TB Centre and Department of Paediatrics and Child Health, Tygerberg Children s Hospital, Stellenbosch University, Cape Town, South Africa bjmarais sun ac za
Arch Dis Child 91:762-5. 2006Current international guidelines recommend 6-9 months of isoniazid (INH) preventive chemotherapy to prevent the development of active tuberculosis in children exposed to a susceptible strain of M tuberculosis...
- Three months of rifapentine and isoniazid for latent tuberculosis infectionTimothy R Sterling
Vanderbilt University School of Medicine, Nashville, TN, USA
N Engl J Med 365:2155-66. 2011..The current standard regimen of isoniazid for 9 months is efficacious but is limited by toxicity and low rates of treatment completion.
- Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South AfricaP Kiepiela
Department of Virology, University of Natal, Faculty of Medicine, Durban, South Africa
Tuber Lung Dis 80:47-56. 2000Genotypic analysis of isoniazid (INH) resistance in 79 isolates of M...
- Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trialA Jindani
International Union Against Tuberculosis and Lung Disease, 68 boulevard Saint Michel, 75006 Paris, France
Lancet 364:1244-51. 2004A WHO-recommended 8-month regimen based on ethambutol and isoniazid was evaluated in a randomised clinical trial against a 6-month standard regimen.
- Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910Anne J Lenaerts
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA
Antimicrob Agents Chemother 51:3338-45. 2007..These results show that this acellular rim may, therefore, be a primary location of persisting bacilli withstanding drug treatment...
- Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIVAnand A Date
Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, GA, United States of America
Bull World Health Organ 88:253-9. 2010To measure progress in implementing co-trimoxazole prophylaxis (CTXp) (trimethoprim plus sulfamethoxazole) and isoniazid preventive therapy (IPT) policy recommendations, identify barriers to the development of national policies and ..
- The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, CambodiaB S Sutton
Department of Finance, Economics and Quantitative Methods, University of Alabama at Birmingham, Birmingham, Alabama 35294 4460, USA
Int J Tuberc Lung Dis 13:713-8. 2009..The current study evaluates one of four pilot sites initiated in Cambodia to establish feasible and effective ways to manage patients with human immunodeficiency virus (HIV) infection and tuberculosis (TB)...
- mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatisMaria R Pasca
Dipartimento di Genetica e Microbiologia, University of Pavia, Via Ferrata 1, 27100 Pavia, Italy
Antimicrob Agents Chemother 49:4775-7. 2005..gene, encoding a hypothetical resistance nodulation division transporter, confers a high resistance level to isoniazid when overexpressed in Mycobacterium smegmatis...
- Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentineMarc Weiner
University of Texas Health Science Center, South Texas Veterans Health Care System, San Antonio 78284, USA
Am J Respir Crit Care Med 167:1341-7. 2003To understand why once-weekly isoniazid/rifapentine therapy for tuberculosis was less effective than twice-weekly isoniazid/rifampin, we studied human immunodeficiency virus-seronegative patients with either failure (n = 4), relapse (n = ..
- Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, BrazilAlmério Machado
Escola Bahiana de Medicina e Saude Publica, Salvador, Bahia, Brazil
Int J Tuberc Lung Dis 13:719-25. 2009..Although treatment of latent tuberculosis infection (LTBI) is an essential component of tuberculosis (TB) control in countries such as the United States, it is not widely practiced in most TB-endemic countries...
- Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected miceMi Sun Koo
Laboratory of Mycobacterial Immunity and Pathogenesis, The Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States of America
PLoS ONE 6:e17091. 2011..study, we compared bacillary clearance from the lungs of Mtb-infected mice treated with the anti-TB drug isoniazid (INH) in the presence and absence of an immunomodulatory phosphodiesterase 4 inhibitor (PDE4i), CC-3052...
- Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006Barudi Mosimaneotsile
BOTUSA, Gaborone and Francistown, Botswana
J Acquir Immune Defic Syndr 54:71-7. 2010To describe reasons for exclusion from isoniazid tuberculosis preventive therapy (IPT) and outcomes of persons living with HIV (PLWH) during 6 months of IPT.
- Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosisSrinivas V Ramaswamy
Houston Tuberculosis Initiative, Department of Pathology, Baylor College of Medicine, University of Texas Medical School, Houston, Texas 77030, USA
Antimicrob Agents Chemother 47:1241-50. 2003b>Isoniazid (INH) is a central component of drug regimens used worldwide to treat tuberculosis. Previous studies have identified resistance-associated mutations in katG, inhA, kasA, ndh, and the oxyR-ahpC intergenic region...
- Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humansAlexander S Pym
Unite de Genetique Moleculaire Bacterienne, Institut Pasteur, Paris, France
Infect Immun 70:4955-60. 2002The usefulness of isoniazid (INH), a key component of short-course chemotherapy of tuberculosis, is threatened by the emergence of drug-resistant strains of Mycobacterium tuberculosis with mutations in the katG gene...
- Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosisAdithya Cattamanchi
Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco GeneralHospital, 1001 Potrero Ave, San Francisco, CA 94110, USA
Clin Infect Dis 48:179-85. 2009Risk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described.
- Use of isoniazid for latent tuberculosis infection in a public health clinicPhilip A Lobue
Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention, Division of Tuberculosis Elimination, Field Services Branch, P O Box 85222, Mail Stop P511D, San Diego, CA 92186 5222, USA
Am J Respir Crit Care Med 168:443-7. 2003b>Isoniazid is an efficacious treatment for latent tuberculosis. Concerns remain, however, regarding hepatotoxicity associated with this medication...
- Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosisD R Sherman
Laboratory of Tuberculosis and Molecular Microbiology, PathoGenesis Corporation, Seattle, Washington 98119, USA
Science 272:1641-3. 1996Mutations that eliminate KatG catalase-peroxidase activity prevent activation of isoniazid and are a major mechanism of resistance to this principal drug for the treatment of Mycobacterium tuberculosis infections...
- Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitisYi Shin Huang
Division of Gastroenterology, Department of Medicine, and Chest Department, Taipei Veterans General Hospital and National Yang Ming University School of Medicine, Taipei, Taiwan
Hepatology 35:883-9. 2002Antituberculosis drug-induced hepatitis is one of the most prevalent drug-induced liver injuries. Isoniazid is the major drug incriminated in this hepatotoxicity...
- The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, BrazilJonathan E Golub
Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland 21231, USA
AIDS 21:1441-8. 2007..Antiretroviral therapy (ART) lowers the risk of tuberculosis, but may not be sufficient to control HIV-related tuberculosis. Isoniazid preventive therapy (IPT) reduces tuberculosis incidence significantly, but is not widely used.
- The mechanism of isoniazid killing: clarity through the scope of geneticsCatherine Vilcheze
Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, New York 10461, USA
Annu Rev Microbiol 61:35-50. 2007b>Isoniazid (INH) is one of the most efficient drugs for the treatment of Mycobacterium tuberculosis infections. Despite its rather simple chemical structure, the mechanism by which INH kills M. tuberculosis is complex...
- Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysisFreddie Bwanga
Department of Medical Microbiology Makerere University College of Health Sciences Kampala, Uganda
BMC Infect Dis 9:67. 2009..testing tests with the conventional indirect testing for detection of resistance to rifampicin and isoniazid in M. tuberculosis...
- Passive versus active tuberculosis case finding and isoniazid preventive therapy among household contacts in a rural district of MalawiR Zachariah
Operational Research HIV TB, Medical Department, Médecins sans Frontières Brussels Operational Centre, Brussels, Belgium
Int J Tuberc Lung Dis 7:1033-9. 2003..Thyolo district, rural Malawi...
- New regimens to prevent tuberculosis in adults with HIV infectionNeil A Martinson
Center for Tuberculosis Research and Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
N Engl J Med 365:11-20. 2011..We evaluated three new regimens for latent tuberculosis that may be more potent and durable than standard isoniazid treatment.
- The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis--an enzyme which inactivates the anti-tubercular drug, isoniazidJames Sandy
Department of Pharmacology, University of Oxford, Mansfield Road, OX1 3QT, UK
J Mol Biol 318:1071-83. 2002Arylamine N-acetyltransferases which acetylate and inactivate isoniazid, an anti-tubercular drug, are found in mycobacteria including Mycobacterium smegmatis and Mycobacterium tuberculosis...
- Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosisDeepak Almeida
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Antimicrob Agents Chemother 53:4178-84. 2009To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and ..
- Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosisHiroki Ando
Department of Infectious Diseases, Research Institute, International Medical Center of Japan, Tokyo, Japan
Antimicrob Agents Chemother 54:1793-9. 2010b>Isoniazid (INH) is an effective first-line antituberculosis drug. KatG, a catalase-peroxidase, converts INH to an active form in Mycobacterium tuberculosis, and katG mutations are major causes of INH resistance...
- Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growthTawanda Gumbo
Emerging Infections and Host Defenses Section, Ordway Research Institute, Albany, NY, USA
J Infect Dis 195:194-201. 2007It is believed that the cessation of isoniazid's early bactericidal activity during the initial phase of antituberculosis therapy is due to the depletion of Mycobacterium tuberculosis in the exponential phase of growth...
- Treatment of isoniazid-resistant pulmonary tuberculosisYee Hyung Kim
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
BMC Infect Dis 8:6. 2008Although resistance to isoniazid (INH) is the most common form of drug resistance seen among Mycobacterium tuberculosis isolates, there have been few studies on the efficacy and optimal duration of treatment for patients with INH-..
- Molecular analysis of isoniazid-resistant Mycobacterium tuberculosis isolates from England and Wales reveals the phylogenetic significance of the ahpC -46A polymorphismL V Baker
HPA Mycobacterium Reference Unit, Department of Microbiology, Guy s, King s and St Thomas School of Medicine, King s College Hospital, East Dulwich Grove, London SE22 8QF, United Kingdom
Antimicrob Agents Chemother 49:1455-64. 2005..investigated the prevalence and diagnostic potential of the most commonly reported mutations associated with isoniazid resistance, katG 315Thr, katG 315Asn, inhA -15T, inhA -8A, and the oxyR-ahpC intergenic region, in a population ..
- An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazidThomas M Polasek
Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Adelaide, Australia
Br J Clin Pharmacol 61:570-84. 2006To characterize potential mechanism-based inactivation (MBI) of major human drug-metabolizing cytochromes P450 (CYP) by monoamine oxidase (MAO) inhibitors, including the antitubercular drug isoniazid.
- Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapyCaroline Colijn
Department of Engineering Mathematics, University of Bristol, Bristol, United Kingdom
PLoS ONE 6:e18327. 2011..This finding suggests that multidrug resistant M. tb may not be an entirely "man-made" phenomenon and may help explain how highly drug resistant forms of TB have independently emerged in many settings...
- Survey of isoniazid preventive therapy in South Africa, 2011J C Chehab
Centers for Disease Control and Prevention, Pretoria, South Africa
Int J Tuberc Lung Dis 16:903-7. 2012..Public health facilities in South Africa...
- Spoligotype-based comparative population structure analysis of multidrug-resistant and isoniazid-monoresistant Mycobacterium tuberculosis complex clinical isolates in PolandTomasz Jagielski
Department of Microbiology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
J Clin Microbiol 48:3899-909. 2010..in Poland (n = 46), representing all culture-positive MDR tuberculosis (MDR-TB) cases, was compared to that of isoniazid (INH)-monoresistant strains (n = 71) isolated in 2004. The latter data set from a previous study (E...
- Isoniazid preventive therapy in correctional facilities: a systematic reviewH A A Al-Darraji
Centre of Excellence for Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia
Int J Tuberc Lung Dis 16:871-9. 2012..b>Isoniazid preventive therapy (IPT) represents an effective and cost-effective measure...
- Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than ratsImir G Metushi
Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Chem Res Toxicol 25:2567-76. 2012b>Isoniazid (INH) is associated with serious liver injury and autoimmunity. Classic studies in rats indicated that a reactive metabolite of acetylhydrazine is responsible for the covalent binding and toxicity of INH...
- Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009M Gegia
The National Center for TB and Lung Diseases, Georgia, Tbilisi, Georgia
Int J Tuberc Lung Dis 16:812-6. 2012The optimal management strategy for patients with isoniazid (INH) monoresistant forms of tuberculosis (TB) has been widely debated...
- Primary isoniazid prophylaxis against tuberculosis in HIV-exposed childrenShabir A Madhi
Department of Science and Technology National Research Foundation Vaccine Preventable Diseases and the Medical Research Council Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa
N Engl J Med 365:21-31. 2011..We conducted a double-blind, randomized, placebo-controlled trial of preexposure isoniazid prophylaxis against tuberculosis in HIV-infected children and uninfected children exposed to HIV during the ..
- Molecular characteristics of rifampin- and isoniazid-resistant mycobacterium tuberculosis strains isolated in VietnamNghiem Ngoc Minh
Institute of Biotechnology, Vietnam Academy of Science and Technology, Hospital 103, Vietnam Military Medical University, Vietnam
J Clin Microbiol 50:598-601. 2012..A total of 166 rifampin (RIF)- and/or isoniazid (INH)-resistant strains of M...
- Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South AfricaKaren R Jacobson
Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Clin Infect Dis 53:369-72. 2011We report treatment outcomes from a retrospective cohort of patients with isoniazid-monoresistant tuberculosis in rural South Africa...
- Adherence to treatment of latent tuberculosis infection in a clinical population in New York CityJiehui Li
New York City Department of Health and Mental Hygiene NYCDOHMH, 26th Floor, New York, NY 10279 2600, USA
Int J Infect Dis 14:e292-7. 2010..Low adherence to treatment of latent tuberculosis infection (TLTBI) diminishes TB prevention efforts. This study examined the treatment completion rate among those who started TLTBI and factors associated with adherence to TLTBI...
- Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, UzbekistanS Hofmann-Thiel
IML, Institute of Microbiology and Laboratory Medicine, Supranational Reference Laboratory SNRL, Asklepios Fachkliniken, Robert Koch Allee 2, D 82131 Gauting, Germany
Eur Respir J 33:368-74. 2009..Nehren, Germany), which is designed to detect genetic mutations associated with resistance to rifampin and isoniazid. Cases of heteroresistance were further subjected to genotyping using mycobacterial interspersed repetitive unit-..
- Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in BotswanaDeborah A Gust
Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
PLoS ONE 6:e18435. 2011..Participant non-adherence and loss to follow-up can compromise the validity of clinical trial results. An assessment of these issues was made in a 3-year tuberculosis prevention trial among HIV-infected adults in Botswana...
- Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infectionAlimuddin Zumla
Department of Infection, University College London Medical School, London, UK
Trop Med Int Health 16:79-83. 2011..In this viewpoint, widely held assumptions on Mtb latency and isoniazid monotherapy and chemoprophylaxis are challenged...
- The value of urine testing for verifying adherence to anti-tuberculosis chemotherapy in children and adults in UgandaP E Meissner
Liverpool School of Tropical Medicine, UK
Int J Tuberc Lung Dis 6:903-8. 2002..Mulago Hospital, Kampala, Uganda...
- Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trialChristian Lienhardt
Clinical Trial Division, International Union Against Tuberculosis and Lung Disease, Paris, France
JAMA 305:1415-23. 2011..Fixed-dose combinations (FDCs) of drugs for treatment of tuberculosis have been advocated to prevent the emergence of drug resistance...
- Point-of-care Arkansas method for measuring adherence to treatment with isoniazidRenata L Guerra
Tuberculosis Clinical Research Laboratory, Institute of Thoracic Diseases, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Respir Med 104:754-7. 2010We evaluated the accuracy of a point-of-care test designed to measure adherence to isoniazid (INH) preventive therapy in a hospital setting in Rio de Janeiro, Brazil...
- Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazidFeng Wang
Department of Biochemistry and Biophysics, Texas A and M University, College Station, Texas 77843 2128, USA
Antimicrob Agents Chemother 54:3776-82. 2010Mycobacterium tuberculosis enoyl-acyl-ACP reductase (InhA) has been demonstrated to be the primary target of isoniazid (INH). Recently, it was postulated that M...
- Inconsistent dosing of anti-tuberculosis drugs in Taipei, TaiwanC Y Chiang
International Union Against Tuberculosis and Lung Disease, Paris, France
Int J Tuberc Lung Dis 14:878-83. 2010..Taipei City, Taiwan...
- Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence settingClare L van Halsema
London School of Hygiene and Tropical Medicine, London, UK
AIDS 24:1051-5. 2010..World Health Organization recommendations, concerns about promoting resistance have impeded implementation of isoniazid preventive therapy (IPT) for tuberculosis (TB)...
- Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in ratsP J O'Brien
Safety Assessment, GlaxoSmithKline, Park Road, Ware SG12 0DP, UK
Lab Anim 36:313-21. 2002..of hepatic injury, including partial hepatectomy and exposure to methapyrilene, dexamethasone, cyproterone, isoniazid, lead nitrate, and Wyeth-14643...
- Isoniazid preventive therapy and risk for resistant tuberculosisMaria Elvira Balcells
Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom
Emerg Infect Dis 12:744-51. 2006In the context of tuberculosis (TB) resurgence, isoniazid preventive therapy (IPT) is increasingly promoted, but concerns about the risk for development of isoniazid-resistant tuberculosis may hinder its widespread implementation...
- Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated miceNeeraj Dhar
Global Health Institute, Swiss Federal Institute of Technology EPFL, 1015 Lausanne, Switzerland
Proc Natl Acad Sci U S A 107:12275-80. 2010..we identified mutations in Mycobacterium tuberculosis that impaired or enhanced persistence in mice treated with isoniazid (INH), a front-line anti-TB drug...
- Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populationsTawanda Gumbo
Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
Antimicrob Agents Chemother 51:2329-36. 2007b>Isoniazid, administered as part of combination antituberculosis therapy, is responsible for most of the early bactericidal activity (EBA) of the regimen...
- Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathologySelvakumar Subbian
Laboratory of Mycobacterial Immunity and Pathogenesis, The Public Health Research Institute at the University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA
Am J Pathol 179:289-301. 2011..inhibitor that dampens the innate immune response, on the outcome of treatment with the antibiotic isoniazid. Our data show that cotreatment of M...
- Completion of isoniazid preventive therapy among HIV-infected patients in TanzaniaP J Munseri
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Int J Tuberc Lung Dis 12:1037-41. 2008b>Isoniazid preventive therapy (IPT) has not been widely implemented due to questions about acceptance, adherence and side effects.
- inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosisA Banerjee
Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 10461
Science 263:227-30. 1994b>Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown...
- Recording isoniazid preventive therapy delivery to children: operational challengesS S Van Wyk
Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa
Int J Tuberc Lung Dis 14:650-3. 2010Despite recommendations to provide isoniazid preventive therapy (IPT) to eligible children aged <5 years who are in close contact with an infectious tuberculosis (TB) case, IPT delivery in high-burden settings remains poor...
- Screening childhood contacts of patients with smear-positive pulmonary tuberculosis in MalawiN J M Claessens
Academic Medical Centre, University of Amsterdam, The Netherlands
Int J Tuberc Lung Dis 6:362-4. 2002..Of the 365 young children, 33 (9%) were screened for TB--23 received isoniazid preventive therapy, six received anti-tuberculosis treatment, and in four no action was taken...
- The HIV-associated tuberculosis epidemic--when will we act?Anthony D Harries
International Union Against Tuberculosis and Lung Disease, Paris, France
Lancet 375:1906-19. 2010..Implementation of the 3Is policy (intensified tuberculosis case finding, infection control, and isoniazid preventive therapy) for prevention of HIV-associated tuberculosis, combined with earlier start of ART, will ..
- Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South AmericaElis R Dalla Costa
State Foundation for Production and Research in Health FEPPS, Porto Alegre, Brazil
BMC Microbiol 9:39. 2009..limited sample sizes have separately evaluated mutations in katG, ahpC and inhA genes that are associated with isoniazid (INH) resistance...
- Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trialSoumya Swaminathan
Tuberculosis Research Center, Indian Council of Medical Research, Chetput, Chennai, India
Am J Respir Crit Care Med 181:743-51. 2010..The outcome of fully intermittent thrice-weekly antituberculosis treatment of various durations in HIV-associated tuberculosis is unclear...
- Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungsSelvakumar Subbian
Laboratory of Mycobacterial Immunity and Pathogenesis, the Public Health Research Institute PHRI at the University of Medicine and Dentistry of New Jersey UMDNJ, Newark, New Jersey, United States of America
PLoS Pathog 7:e1002262. 2011..to examine the crosstalk between host and pathogen in rabbits with pulmonary TB during treatment with isoniazid (INH)...
- New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variabilityTawanda Gumbo
Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
Antimicrob Agents Chemother 54:1484-91. 2010..The critical concentration of isoniazid is either 0.2 or 1.0 mg/liter, that of rifampin is 1...
- Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampinHassan Safi
Division of Infectious Disease and Center for Emerging Pathogens, Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07103, USA
Antimicrob Agents Chemother 52:2027-34. 2008..All parental and isogenic mutant strains had identical isoniazid (INH) and rifampin (RIF) MICs...
- Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosisCatherine Vilcheze
Howard Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Mol Microbiol 69:1316-29. 2008..mutants of Mycobacterium tuberculosis that were resistant to the anti-tuberculosis drugs ethionamide and isoniazid were isolated and found to map to mshA, a gene encoding the first enzyme involved in the biosynthesis of ..
- CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosisNicolas Vuilleumier
Central Clinical Chemistry Laboratory, Department of Clinical Pathology, Geneva University Hospital, 24 Micheli du Crest, 1211, Geneva 14, Switzerland
Eur J Clin Pharmacol 62:423-9. 2006....
- Limited utility of name-based tuberculosis contact investigations among persons using illicit drugs: results of an outbreak investigationRana Jawad Asghar
Epidemic Intelligence Service, Office of Workforce and Career Development and Division of Global Public Health Capacity Development, Centers for Disease Control and Prevention, Atlanta, GA, USA
J Urban Health 86:776-80. 2009..Between January 2004 and May 2005, 18 isoniazid-resistant TB cases with matching Mycobacterium tuberculosis genotypes (spoligotypes) were reported in Miami; ..
- Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse populationSo Yamada
Canada s Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada
Pharmacogenomics 10:1433-45. 2009TB is a serious global public health problem. Isoniazid, a key drug used to treat latent TB, can cause hepatotoxicity in some patients...
- Treatment of latent infection with Mycobacterium tuberculosis: update 2010C C Leung
Tuberculosis and Chest Service, Dept of Health, Grantham Hospital, Hong Kong, China
Eur Respir J 37:690-711. 2011..Randomised controlled trials have established protective efficacy of isoniazid therapy for 6-12 months among non-HIV-infected and HIV-infected subjects...
- Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative studyRebecca Lester
London School of Hygiene and Tropical Medicine, London, UK
AIDS 24:S45-8. 2010Despite good evidence that isoniazid preventive therapy (IPT) reduces incidence of tuberculosis among people with HIV infection, implementation of IPT is low...
- Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugsAnuj Kumar Gupta
Department of Microbiology and Molecular Biology, National JALMA Institute for Leprosy and Other Mycobacterial Diseases NJILOMD, Agra, India
Microb Drug Resist 16:21-8. 2010..of efflux pump genes Rv2459, Rv3728, and Rv3065 was associated with resistance to the combination of isoniazid and ethambutol, and these drugs, along with streptomycin, were identified to group together, where efflux-..
- Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistanceIndra L Bergval
KIT Biomedical Research, Royal Tropical Institute, Amsterdam, The Netherlands
J Antimicrob Chemother 64:515-23. 2009The high prevalence of isoniazid-resistant Mycobacterium tuberculosis is often explained by a high mutation rate for this trait, although detailed information to support this theory is absent...
- Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3AZ Desta
Division of Clinical Pharmacology, Department of Medicine, Georgetown University Medical Center, Washington, DC 20007, USA
Antimicrob Agents Chemother 45:382-92. 2001b>Isoniazid (INH) remains the most safe and cost-effective drug for the treatment and prophylaxis of tuberculosis...
- Vaccine-induced immunity circumvented by typical Mycobacterium tuberculosis Beijing strainsKristin Kremer
National Institute for Public Health and the Environment, Bilthoven, The Netherlands
Emerg Infect Dis 15:335-9. 2009..The strains' associations with drug resistance, M. bovis BCG vaccination, and patient characteristics were assessed. BCG vaccination may have positively selected the prevalent typical Beijing strains...
- Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South AfricaJ H Day
London School of Hygiene and Tropical Medicine, London, United Kingdom
Int J Tuberc Lung Dis 10:523-9. 2006..Human immunodeficiency virus (HIV) clinic for employees of a gold mine, Free State, South Africa...
- Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in UgandaHeidi Albert
Foundation for Innovative New Diagnostics, Kampala, Uganda
BMC Infect Dis 10:41. 2010..Line probe assays (LPAs) have been recently approved for use in low income settings and can be used to screen smear-positive sputum specimens for resistance to rifampicin and isoniazid in 1-2 days.
- Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysisMohamed Abdel Aziz
Stop TB Department, WHO, Geneva, Switzerland
Lancet 368:2142-54. 2006..This study aimed to analyse data on antituberculosis drug resistance gathered by the WHO and International Union Against Tuberculosis and Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance...
- High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001Igor Mokrousov
Laboratory of Molecular Microbiology, St Petersburg Pasteur Institute, St Petersburg, Russia
Antimicrob Agents Chemother 46:1417-24. 2002A total of 204 isoniazid (INH)-resistant strains of Mycobacterium tuberculosis isolated from different patients in the northwestern region of Russia from 1996 to 2001 were screened by a PCR-restriction fragment length polymorphism (RFLP) ..
- Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampinAlfred Lardizabal
Global Tuberculosis Institute, School of Public Health, New Jersey Medical School, 225 Warren St, Second Floor, Newark, NJ 07103, USA
Chest 130:1712-7. 2006b>Isoniazid is the standard medication used to treat latent tuberculosis infection (LTBI)...
- Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health OF Gordin
Veterans Affairs Medical Center and Georgetown University, Washington, DC 20422, USA
JAMA 283:1445-50. 2000Because of problems with adherence, toxicity, and increasing resistance associated with 6- to 12-month isoniazid regimens, an alternative short-course tuberculosis preventive regimen is needed.
- Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pigZahoor Ahmad
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21289, USA
J Infect Dis 200:1136-43. 2009The marked reduction in the potent early bactericidal activity of isoniazid during the initial phase of antituberculosis (anti-TB) therapy has been attributed not only to the depletion of logarithmically growing bacilli but also to the ..
- Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in KuwaitS Ahmad
Department of Microbiology, Kuwait University, P O Box 24923, Safat 13110, Kuwait
Tuberculosis (Edinb) 87:123-9. 2007..Recent reports of embB306 mutations in ethambutol-resistant and ethambutol-susceptible drug-resistant strains of Mycobacterium tuberculosis have questioned the significance of these mutations in conferring resistance to ethambutol (EMB)...
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialMarcus B Conde
Instituto de Doencas do Torax Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Lancet 373:1183-9. 2009..The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the initial stage of tuberculosis treatment...
- Prevalence of tuberculosis drug resistance in 10 provinces of ChinaGuang Xue He
National Center for TB control and prevention, China Center for Disease Control and Prevention CDC, Beijing, PR China
BMC Infect Dis 8:166. 2008..The emergence of drug-resistant tuberculosis (TB) hampers TB control. Ten provinces in China performed drug resistance surveys among tuberculosis (TB) patients in 1996-2004 to assess levels of drug resistance...
- Using PET isotopes to identify drug targets and to diagnose infectious diseasesPeter J Tonge; Fiscal Year: 2010..11C) and fluorine-18 (18F), will be incorporated into current antibiotics, such as the tuberculosis drugs isoniazid and rifampicin, in order to directly identify the protein target(s) for these molecules in living cells...
- Immune-based detection of rifampicin-resistance in HIV/TBGregory P Bisson; Fiscal Year: 2013..HIV increases the risk of TB, and multi-drug resistant TB (MDR-TB), defined as TB resistant to both isoniazid (INH) and rifampicin, has become a public health emergency in some parts of sub-Saharan Africa, where the HIV ..
- Novel Spectinamide Antibiotics for the Treatment of MDR/XDR TuberculosisMichelle M Butler; Fiscal Year: 2013..involving strains that are multidrug-resistant (MDR), which is defined as being resistant to treatment with isoniazid and rifampicin, the two first-line antibiotics for TB therapy and those that are extensively drug-resistant ..
- Mode of Action of Thiorcarlide in Mycobacterium TuberculosisMary Jackson; Fiscal Year: 2012..Mycobacterium aurum, the second target of the drug is likely to differ from that of other anti-TB drugs such as isoniazid and ethionamide and could be an enzyme introducing early functional groups into the meromycolate chain of ..
- Investigation of synergy between Rifampin and SQ109, a new anti-TB drug candidateVENKATA REDDY; Fiscal Year: 2009..Importantly, when used in combination with rifampin (RIF) + isoniazid (INH) + pyrazinamide (PZA), SQ109 is able to increase bacterial killing and reduce the time by at least 25% to ..
- Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugsVenkata M Reddy; Fiscal Year: 2010..SQ641 has activity superior to Isoniazid (INH) and all other TB drugs and, under appropriate conditions, rapidly reduces Mycobacteria in our two best TB ..
- A cell-based HTS for delayed death inhibitors of the malarial parasite plastidDAVID FIDOCK; Fiscal Year: 2009..Assay development will be guided using the reference compounds azithromycin, chloroquine and isoniazid (representing delayed death, fast-acting and inactive compounds respectively) and configured for HTS using a ..
- Impact of a New Molecular TB Test on TB/HIV Outcomes among HIV-Infected MalawiansRichard E Chaisson; Fiscal Year: 2013..World Health Organization (WHO) has recommended that the Three I's - intensified case-finding for TB (ICF), isoniazid preventive therapy (IPT) and infection control for TB -be targeted at PLWHA...
- Development of adamantyl ureas against MDR/XDR M.tbMary Jackson; Fiscal Year: 2010..derived lipids suggest that their targets in these pathways differ from those of other anti-TB agents such as isoniazid, ethionamide, thiacetazone and Isoxyl...
- Disrupting Biofilm Formation to Improve TB Drug TreatmentRandall J Basaraba; Fiscal Year: 2013..smegmatis and increases the susceptibility of Mtb to isoniazid. The effectiveness of this strategy will be further tested using our in vitro Mtb drug tolerance assay to show 1)..
- The effect of pncA expression and POA efflux rate in the level of PZA-resistanceMirko J Zimic; Fiscal Year: 2010..In contrast to other antituberculous first line drugs like isoniazid or rifampicin, pyrazinamide has been studied for few groups because: (1) it is used exclusively for tuberculosis ..
- The Role of Cell Wall Lipids in Pathogenesis of Rifampin-Resistant TBPetros C Karakousis; Fiscal Year: 2013..tuberculosis (MDR-TB), defined as Mycobacterium tuberculosis (Mtb) resistant to the two first-line drugs isoniazid and rifampin, has emerged as a major threat to global TB control...
- Epidemiology of multidrug-resistant tuberculosis in PeruMercedes C Becerra; Fiscal Year: 2010..Specific aims are: (1) To measure the within-household transmission of MDR and isoniazid- resistant M. tuberculosis strains compared to drug-sensitive strains...
- Inducible Gene Regulation in MycobacteriaJESSICA CHUANG SEELIGER; Fiscal Year: 2013..The current front-line TB drug isoniazid acts by inhibiting the biosynthesis of an Mtb outer membrane lipid, mycolic acid, underscoring the importance of ..
- Identifying essential functions in non replicating Mycobacterium tuberculosisSARAH S GRANT; Fiscal Year: 2013..PUBLIC RELEVANCE: Despite the use of potent anti-TB agents like isoniazid (INH) and rifampin, the global incidence of tuberculosis has been increasing over the last 25 years, driven by ..
- Improving Pediatric Tb Diagnosis and Management in TanzaniaTania A Thomas; Fiscal Year: 2013..be investigated including drug-resistant TB, serum drug levels to the two most potent first-line TB medications (isoniazid and rifampin), HIV status, nutritional status and concurrent diarrheal illness...
- Stellenbosch University Clinical Trial Unit, Cape Town, South AfricaMARK FREDRIC COTTON; Fiscal Year: 2013..One pediatric study determines the role of isoniazid in preventing tuberculosis (P1041)...
- Mycolate-specific T cell function in human immunity to Mycobacterium tuberculosisAnne Kasmar; Fiscal Year: 2013..Mycolic acid synthesis is the target of the potent anti-mycobacterial agent Isoniazid. Whereas T cells were previously thought to solely recognize peptide antigens, CD1b-restricted human T cells ..
- Bacterial N-Acetyltransferases: Resistance to RegulationJohn S Blanchard; Fiscal Year: 2013..have significant experience in these methods, having recently used them to define the many potential targets for isoniazid in Mycobacterium tuberculosis crude cell extracts...
- MECHANISM BASED INHIBITION OF M TUBERCULOSIS ENZYMESJohn S Blanchard; Fiscal Year: 2012..of tightly binding the isonicotinoyl adducts of NAD and NADP that are the bacteriostatic forms of the prodrug isoniazid. Specifically, we will focus on the ribG-encoded bifunctional deaminase-reductase that is the second step in the ..
- Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant TuberculosisAntonino Catanzaro; Fiscal Year: 2013..e., isoniazid, rifampin, ofloxacin, amikacin, kanamycin, and capreomycin) directly from sputa...
- Wirelessly Observed Therapy to Monitor Treatment of Mycobacterium TuberculosisLorenzo DiCarlo; Fiscal Year: 2013..This Phase I proposal focuses on (1) the development and testing of a combination of the Raisin IEM with isoniazid-rifampin therapy (Isonorif");(2) researching and designing user interfaces specifically for MTB patients and ..
- TB Diagnostics at the Point of CareCHRISTOPHER GERARD COONEY; Fiscal Year: 2013..A low-cost, simple, and rapid point-of-care (POC) test that detects TB and its resistance to first-line drugs (isoniazid, rifampin, ethambutol,and pyrazinamide) would improve TB diagnostics for these minority communities...
- Latent TB Detection and Implications in HIV-1 Infected Women and Their ChildrenGrace C John Stewart; Fiscal Year: 2010..Because detection of LTBI by immunodiagnostics indicate need for isoniazid (INH) prophylaxis, prospective studies to define predictive value of IGRAs are not feasible...
- Immune Activation and Isoniazid Metabolism in HIV/TBGregory P Bisson; Fiscal Year: 2013..is the increased risk of liver injury in HIV-infected patients taking the first line anti-tubercular drug isoniazid (INH)...
- Effect of Drug Resistance on Transmissibility and Pathogenicity of M. tuberculosiPhilip C Hopewell; Fiscal Year: 2013DESCRIPTION (provided by applicant): The objective of this study is to determine the effect of isoniazid resistance-conferring mutations alone or in combination with resistance to other drugs (multidrug resistant [MDR] and extensively ..
- Cross-Border Dynamics of MDR/XDR-TB Epidemiology by HIV Status in Tijuana, MexicoRichard Garfein; Fiscal Year: 2009..a 1997 survey found 41% of Tijuana's TB cases were resistant to at least one drug and 17% were resistant to isoniazid and rifampin (MDR-TB), universal drug susceptibility testing (DST) was recommended for all TB cases in Mexico, ..
- A New Therapeutic Regimen for MDR-TBCarol A Nacy; Fiscal Year: 2013..Multidrug-resistant strains of Mtb (resistant to at least isoniazid [INH] and rifampicin [RIF]) result in 440,000 new cases of MDR-TB each year in 41 countries...
- A rapid molecular approach to determine PZA susceptibilityBARRY NEAL KREISWIRTH; Fiscal Year: 2013..The current TB treatment regimen for TB is 2 months of rifampin, isoniazid, ethambutol and pyrazinamide (PZA), followed by 4 months of rifampin and isoniazid...
- Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in ChildrenAWEWURA JACOB KWARA; Fiscal Year: 2013..Aim 1 will determine whether the WHO recommended increased dosages of isoniazid, rifampin, pyrazinamide and ethambutol administered to African children with active TB infection (with or ..
- Species selective dipeptide inhibitors for Mtb proteasomeGang Lin; Fiscal Year: 2013..For example, the two first line anti-Mtb drugs isoniazid and rifampicin kill Mtb rapidly in vitro, but their steriliation abilities are slowed and reduced in vivo...
- Clinical and Molecular Studies of the Erythropoietic Protoporphyria PhenotypeManisha Balwani; Fiscal Year: 2013..A novel FDA-approved pilot study will be conducted in patients with EPP and XLP to determine if Isoniazid, which binds to pyridoxal phosphate, a co-factor of ALAS2, can decrease the activity of ALAS2, thereby reducing ..
- Binational Transmission of Multidrug-Resistant Tuberculosis, California &MexicoTIMOTHY CHARLES RODWELL; Fiscal Year: 2012..is caused by Mycobacterium tuberculosis strains that are resistant to the two most effective anti-TB drugs: isoniazid (INH) and rifampin (RIF)...
- The Utility of Interferon-Gamma Release Assays in TB-HIV co-infected ChildrenAnna M Mandalakas; Fiscal Year: 2011..the influence of additional modifiers including time since exposure, anti-retroviral therapy, HIV viral load and isoniazid therapy...
- MAS-PCR Rapid Screening Test for Multidrug-Resistant Tuberculosis (MDR-TB)Angkana Chaiprasert; Fiscal Year: 2013..MDR-TB is defined as resistance to both rifampicin (RIF) and isoniazid (INH), two of the first-line drugs used for treatment of TB...
- Optimal dosing of 1st line antituberculosis and antiretroviral drugs in childrenHelen McIlleron; Fiscal Year: 2013..Recent studies suggest that first line anti-TB drugs (isoniazid, rifampin, ethambutol and pyrazinamide) are often under-dosed in adults, especially with HIV, and children...
- Plasma and Intrapulmonary Pharmacokinetics and Pharmacodynamics (PKPD) of AerosolJeffrey Golden; Fiscal Year: 2010..The specific aim of this project is to plan a clinical trial that will administer aerosolized isoniazid (INH), rifampin (RIF) and streptomycin (SM) to healthy volunteers and measure the concentration of each drug in ..
- PHARMACOKINETICS AND TOXICITY OF 2ND LINE ANTI-TB DRUGS IN HIV-INFECTED CHILDRENANNEKE CATHARINA HESSELING; Fiscal Year: 2013..Multidrug-resistant TB (MDR-TB;i.e. resistance to both rifampin and isoniazid) is an emerging epidemic, with an estimated 489 000 global cases annually...
- INCIDENCE, DETERMINANTS AND OUTCOMES OF LATENT AND ACTIVE TUBERCULOSIS AMONG HIVBETTY KINTU NSANGI; Fiscal Year: 2013..Treatment of children with latent TB and general treatment of HIV-infected children with isoniazid will also provide essential information as the country prepares to adopt the new WHO Isoniazid Preventive ..
- Development of a second generation MDR-XDR TB assayDavid Alland; Fiscal Year: 2013..the many targets and mutations required for MTB and mycobacteria other than tuberculosis (MOTT) detection and isoniazid (INH), rifampin (RIF) and fluoroquinolone (FQ) antibiotic resistance testing in a single real-time PCR tube...
- Evaluation of a highly-informative LATE-PCR single-tube assay for M(X)DR-TBRobin Mark Warren; Fiscal Year: 2013..Accordingly, the WHO approved the use of Line Probe assays for the detection of M. tuberculosis complex and isoniazid and/or rifampin...
- Mechanisms of adverse effects of anti-tuberculosis drugsXiaochao Ma; Fiscal Year: 2013..The objective of this application is to determine the mechanism of liver injury associated with rifampicin and isoniazid co-therapy...
- Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in BrazilJonathan E Golub; Fiscal Year: 2013..Delays in TST and provision of isoniazid preventive therapy in Rio de Janeiro are extremely long, and risk of TB disease is quite high among HIV-infected ..
- Discovery of novel agents against M. tuberculosis.ESTEBAN EDWARD MENA; Fiscal Year: 2010..has been unchanged since the 1980s and relies on two months of intensive, directly observed therapy with isoniazid, rifampicin, pyrazinamide, and ethambutol followed by a minimum of four months of isoniazid and rifampicin...
- Optimizing the impact of Xpert MTB/RIF on treatment outcomes of drug resistant TBANNELIES T A VAN RIE; Fiscal Year: 2013..7 million deaths in 2009. Multidrug resistant TB (MDR-TB, defined as resistance to at least isoniazid and rifampicin), and HIV-associated TB pose important threats to TB control...
- Optimal Drug Regimens for TB: An Integrated Computational/Experimental ApproachMichael A Lyons; Fiscal Year: 2013..While we seek to establish the feasibility of the proposal using current front-line anti-TB drugs (isoniazid, rifampin, pyrazinamide), the ultimate aim of this project is the application of the methodology to the newer ..
- Nanoparticle delivery system for antiturberculosis drugLeonid Heifets; Fiscal Year: 2004..Our preliminary data, the only data on anti-TB drugs, suggest that the MICs for streptomycin and isoniazid were reduced by 4.5-7 fold. Dr...
- Identification of factors that control Mycobacterium tuberculosis biofilm growthAnil Kumar Ojha; Fiscal Year: 2010..Upon evaluation of tolerance properties of M. tuberculosis biofilms against rifampicin and isoniazid we found that a significantly large number of bacilli in biofilms developed phenotypic resistance against both ..
- A Combination Intervention Package for Isoniazid Preventive Therapy in EthiopiaANDREA ALLOCCO HOWARD; Fiscal Year: 2013..1 million people are living with HIV. Strong scientific evidence demonstrates that isoniazid preventive therapy (IPT) reduces the risk of TB among HIV-infected individuals...
- Chemotherapeutics Against Multi-Drug Resistant TuberculosisPeter J Tonge; Fiscal Year: 2010..hypothesis that compounds that do not require activation by the mycobacterial KatG enzyme will be active against isoniazid-resistant clinical strains...
- Drugs targeting persistent Mycobacterium TuberculosisWILLIAM ROBERT JACOBS; Fiscal Year: 2013..activity against both drug susceptible and drug resistant Mtb and synergizes with rifampcin (RIF) or isoniazid (INH) in sterilization of Mtb in vitro...
- Mathematical Modeling in Clinical Trials of Tuberculosis TherapeuticsDAVID PRESTON HOLLAND; Fiscal Year: 2013..3 specific aims: Aim 1 will be to use the model to examine the potential impact of substituting moxifloxacin for isoniazid during the first two months of TB treatment on TB relapse rates, given standard and abbreviated treatment ..
- Advancing lead dipiperidine compound into preclinical developmentMarina Protopopova; Fiscal Year: 2009..strains of TB (XDR-TB) that are resistant to the two most important front- line TB drugs, rifampicin and isoniazid, and also resistant to at least two classes of second-line drugs...
- Catalysis of Isoniazid action by M. tuberculosis catalase-peroxidaseRichard S Magliozzo; Fiscal Year: 2010..tuberculosis relevant to the mechanism of action of the antituberculosis antibiotic isoniazid (INH)...
- Improving Isoniazid Preventive Therapy Penetration through Intensification of CasAnthony Moll; Fiscal Year: 2013Philanjalo CDC Grant Application, FOA CDC-RFA-GH-11-005 Project Abstract "Improving Isoniazid Preventive Therapy Penetration among HIV infected Individuals through Intensification of Case Finding at the Community Level in Rural South ..
- DISSEMINATED TUBERCULOSIS IN HIV INFECTIONC von Reyn; Fiscal Year: 2004..Subjects with PPD reactions greater than or equal to 5 mm will receive 6 months of prophylaxis with isoniazid. All subjects will be randomized 1:1 to receive a 5-dose series of MV or placebo over 12 months with repeat skin ..
- Community-Based Intensive Case Finding for HIV, TB, and MDR/XDR TB in Rural SouthSheela Shenoi; Fiscal Year: 2013..The WHO has promoted the "3Is" for TB control: intensive case finding (ICF), infection control and isoniazid preventive therapy...
- PRECLINICAL DEVELOPMENT OF NEW ANTITUBERCULOSIS REGIMENLeonid Heifets; Fiscal Year: 2000..of tuberculosis in HIV-infected individuals, growing rates of drug-resistance, the need for alternatives to isoniazid for preventive therapy are among the major problems of tuberculosis today...
- M. AVIUM DISEASE--INHALED LIPOSOME ANTI-TB DRUG THERAPYHans Schreier; Fiscal Year: 1992..killing within alveolar macrophages (AM) and is relatively resistant in vitro to anti-tuberculous drugs such as isoniazid, rifampin, and ethambutol in concentrations currently employed...
- Optimizing NNRTI Doses in Patients with HIV and TBTerrence Blaschke; Fiscal Year: 2007..These subjects will start antituberculous treatment (RMP + isoniazid + pyrazinamide) and 4 weeks later will be randomized between two treatment arms containing different doses of ..
- CHELATION THERAPY OF IRON OVERLOAD WITH PIHGary Brittenham; Fiscal Year: 1993..base condensation of two widely used, inexpensive drugs, vitamin B-6 (pyridoxal) and the antituberculous agent isoniazid (INH). PIH was first recognized as an effective iron chelator in vitro in 1979...
- A New Target for Anti-tuberculosis Agents, FAS 1John Welch; Fiscal Year: 2003..It is the inclusion of pyrazinamide (PZA), an agent with a unique sterilizing activity, with isoniazid and rifampin (RIF) in current treatment regimens that constitutes the basis for 6-month short course therapy for ..
- EFFICACY OF TB CHEMOPROPHYLAXIS IN PPD, HIV ADULTSJacqueline Coberly; Fiscal Year: 1999..Eligible residents of Cite Soleil (n=345) will be randomized to receive isoniazid and pyridoxine (B6) daily for six months, rifampin and B6 daily for three months followed by daily B6 for three ..
- INH-induced lysis of Mycobacterium tuberculosisWilliam Jacobs; Fiscal Year: 2003..Our research program has worked to define the mechanisms of action of a leading anti-tuberculosis drug isoniazid (INH) and an important second line drug ethionamide (ETH), with the goal of enabling rational drug design...
- Target for Mefloquine in MycobacteriaLuiz Bermudez; Fiscal Year: 2002..Furthermore, mefloquine is active against M. avium strain resistant to macrolides, quinolones, isoniazid, ethambutol and rifampin, suggesting a novel mechanism of action...
- Phase II Study of Daily Rifapentine for Pulmonary Tuberculosis (IND 62,611;1/2/0Susan E Dorman; Fiscal Year: 2012..the antimicrobial activity and safety of rifapentine doses of 450 mg and 600 mg administered once daily with isoniazid, pyrazinamide, and ethambutol during intensive phase (first eight weeks) treatment of smear-positive pulmonary ..